Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Genetic polymorphisms and changes can alter GM composition and affect OP risk
Comparison CompoundClassPathway / targetResearch focusFormat 5-Amino-1MQSmall moleculeNNMT inhibitionNAD / SAM metabolismVial 5-Amino-1MQ CapsulesSmall moleculeNNMT inhibitionNAD / SAM metabolismCapsules SLU-PP-332Small moleculePan-ERR agonismMitochondrial gene expressionVial SLU-PP-332 CapsulesSmall moleculePan-ERR agonismMitochondrial gene expressionCapsules Tesofensine CapsulesSmall moleculeMonoamine reuptakeCNS / monoaminergic signallingCapsules Enclomiphene CapsulesSmall moleculeEstrogen receptor (SERM)HPG-axis signallingCapsules AICARSmall moleculeAMPK activationCellular energy sensingVial AOD-9604Peptide fragmenthGH fragment (176-191) signallingLipolytic-pathway signallingVial AOD-9604 CapsulesPeptide fragmenthGH fragment (176-191) signallingLipolytic-pathway signallingCapsules GLP-3 (Reta)PeptideIncretin receptorMetabolic signalling researchVial Every compound in this category is supplied as Research Use Only material with: Peer-reviewed literature and mechanism background underpinning this category are maintained in the linked research articles below
If you have ordered articles with different delivery dates, we send the articles together in one delivery if no other agreement has been made
New experimental and clinical studies should also be proposed to assess the cardioprotective efficacy of incretin-based therapies, as compared to other drug strategies, in patients with or without T2DM in the presence or absence of MI or HF
& Son, M
US$ 29.15
US$ 23.32
US$ 21.36
US$ 28.31
